BUNKER KEVIN D. (Chief Operating Officer) sold 4.5% of their position (5K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $150.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 7/14/2022ACC: 0001725160-22-000133
Officer· Chief Operating Officer
Since Apr 2020
-5K
Net shares
Net seller
$150.1K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
5K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−1.71K
Price / share
$30.02
Trade value
$51.34K
% of position
1.6%
7/13/2022
110K→108.29K
Common Stock
Indirect
Shares
−3.29K
Price / share
$30.01
Trade value
$98.72K
% of position
3.0%
7/14/2022
108.29K→105K
Total
Net shares
−5K
Net value
-$150.06K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 7/13/2022 | S · Sale | −1.71K | $30.02 | $51.34K | 1.6% | 110K | 108.29K |
| Common Stock Indirect | 7/14/2022 | S · Sale | −3.29K | $30.01 | $98.72K | 3.0% | 108.29K | 105K |
| Total | −5K | -$150.06K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned350.00
Common Stock
DirectShares owned764.11K
Total
764.11K direct·350.00 indirect764.46K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 350.00 | Indirect |
| Common Stock | 764.11K | Direct |
| Total | 764.46K | 764.11K direct·350.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported